152 related articles for article (PubMed ID: 37391312)
1. The position of Spy Tag/Catcher system in hepatitis B core protein particles affects the immunogenicity and stability of the synthetic vaccine.
Sheng Y; Li Z; Lin X; Ma Y; Ren Y; Su Z; Ma G; Zhang S
Vaccine; 2023 Jul; 41(33):4867-4878. PubMed ID: 37391312
[TBL] [Abstract][Full Text] [Related]
2. In situ bio-mineralized Mn nanoadjuvant enhances anti-influenza immunity of recombinant virus-like particle vaccines.
Sheng Y; Li Z; Lin X; Wang L; Zhu H; Su Z; Zhang S
J Control Release; 2024 Apr; 368():275-289. PubMed ID: 38382812
[TBL] [Abstract][Full Text] [Related]
3. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
[TBL] [Abstract][Full Text] [Related]
4. SpyTag/SpyCatcher display of influenza M2e peptide on norovirus-like particle provides stronger immunization than direct genetic fusion.
Lampinen V; Gröhn S; Soppela S; Blazevic V; Hytönen VP; Hankaniemi MM
Front Cell Infect Microbiol; 2023; 13():1216364. PubMed ID: 37424789
[TBL] [Abstract][Full Text] [Related]
5. Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology.
Heinimäki S; Lampinen V; Tamminen K; Hankaniemi MM; Malm M; Hytönen VP; Blazevic V
Virology; 2022 Jan; 566():89-97. PubMed ID: 34894525
[TBL] [Abstract][Full Text] [Related]
6. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
7. [Preparation and characterization of HBc virus like particles with site-directed coupling function].
Liu D; Li B; Bi C; Qiao H; Wu X
Sheng Wu Gong Cheng Xue Bao; 2020 Jul; 36(7):1440-1449. PubMed ID: 32748602
[TBL] [Abstract][Full Text] [Related]
8. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
[TBL] [Abstract][Full Text] [Related]
9. Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein.
Ravin NV; Kotlyarov RY; Mardanova ES; Kuprianov VV; Migunov AI; Stepanova LA; Tsybalova LM; Kiselev OI; Skryabin KG
Biochemistry (Mosc); 2012 Jan; 77(1):33-40. PubMed ID: 22339631
[TBL] [Abstract][Full Text] [Related]
10. Development of HBc virus-like particles as modular nanocarrier by intein-mediated trans-splicing.
Wang Z; Tang S; Yue N; Qian Z; Zhou S
Biochem Biophys Res Commun; 2021 Jan; 534():891-895. PubMed ID: 33213839
[TBL] [Abstract][Full Text] [Related]
11. Flagellin/Virus-like Particle Hybrid Platform with High Immunogenicity, Safety, and Versatility for Vaccine Development.
Zhao Y; Li Z; Voyer J; Li Y; Chen X
ACS Appl Mater Interfaces; 2022 May; 14(19):21872-21885. PubMed ID: 35467839
[TBL] [Abstract][Full Text] [Related]
12. Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses.
Zheng D; Chen S; Qu D; Chen J; Wang F; Zhang R; Chen Z
Vaccine; 2016 Dec; 34(51):6464-6471. PubMed ID: 27866773
[TBL] [Abstract][Full Text] [Related]
13. Production and purification of chimeric HBc virus-like particles carrying influenza virus LAH domain as vaccine candidates.
Kazaks A; Lu IN; Farinelle S; Ramirez A; Crescente V; Blaha B; Ogonah O; Mukhopadhyay T; de Obanos MP; Krimer A; Akopjana I; Bogans J; Ose V; Kirsteina A; Kazaka T; Stonehouse NJ; Rowlands DJ; Muller CP; Tars K; Rosenberg WM
BMC Biotechnol; 2017 Nov; 17(1):79. PubMed ID: 29126399
[TBL] [Abstract][Full Text] [Related]
14. Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein.
Xu L; Li Z; Su Z; Yang Y; Ma G; Yu R; Zhang S
Vaccine; 2019 Feb; 37(7):956-964. PubMed ID: 30655174
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
[TBL] [Abstract][Full Text] [Related]
16. A novel rapid modularized hepatitis B core virus-like particle-based platform for personalized cancer vaccine preparation via fixed-point coupling.
Ji M; Zhu J; Xie XX; Liu DQ; Wang B; Yu Z; Liu RT
Nanomedicine; 2020 Aug; 28():102223. PubMed ID: 32422220
[TBL] [Abstract][Full Text] [Related]
17. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.
De Filette M; Martens W; Smet A; Schotsaert M; Birkett A; Londoño-Arcila P; Fiers W; Saelens X
Vaccine; 2008 Dec; 26(51):6503-7. PubMed ID: 18835315
[TBL] [Abstract][Full Text] [Related]
18. A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus.
Wu Y; Zhu R; Xu L; Li Y; Li S; Yu H; Li S; Zhu H; Cheng T; Xia N
Vaccine; 2017 May; 35(20):2728-2735. PubMed ID: 28408118
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety.
Schödel F; Peterson D; Milich D
Intervirology; 1996; 39(1-2):104-10. PubMed ID: 8957676
[TBL] [Abstract][Full Text] [Related]
20. Site-Specific Modification of Virus-Like Particles for Exogenous Tumor Antigen Display and Minimizing Preexisting Immunity.
Cheng K; Ma N; Liang J; Ma X; Feng Q; Liu G; Xu C; Tang M; Zhang L; Gao X; Xu J; Wang C; Zhu F; Wang X; Li X; Zhao X; Nie G
Small; 2023 Jun; 19(23):e2300125. PubMed ID: 36879481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
